Lacey James-Echenique

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “Long term follow-up of a phase II study of cladribine with concurrent rituximab with hairy cell leukemia variant”.

Long term follow-up of a phase II study of cladribine with concurrent rituximab with hairy cell leukemia variant

Blood Advances(2021)10.1182/bloodadvances.2021005039

N/A

0.937DataRank · unranked

28 citations

Evgeny Arons, Maryalice Stetler‐Stevenson, Constance M. Yuan, Hao‐Wei Wang, Hong Zhou +13 more

Phase 2 trial of rituximab with either pentostatin or bendamustine for multiply relapsed or refractory hairy cell leukemia

Blood(2025)10.1182/blood.2025031243

N/A

0.163DataRank · unranked

1 citations

Constance M. Yuan, Hao‐Wei Wang, Chirayu Mohindroo, Hong Zhou, Mark Raffeld +8 more

Phase 1 trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox combined with rituximab for relapsed/refractory hairy cell leukemia.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.7036

N/A

0DataRank · unranked

0 citations

Maryalice Stetler‐Stevenson, Constance M. Yuan, Hao‐Wei Wang, Hong Zhou, Mark Raffeld +10 more